Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Pfizer Inc.’s oral drug tafamidis effective in treating “transthyretin amyloid cardiomyopathy”, a rare and fatal heart disease recently gained approval from the U.S Food and Drug Administration. The drug to be priced at $225,000 a year and will be sold under the brand name Vyndaqel.
The American Pharmaceutical hopes to help 100,000 of patients suffering from the heart disease in the United States, out of which only 2,000 to 5,000 are diagnosed currently. The drug is believed to be able to reduce the risk of death in patients by 30 percent compared to placebo in clinical trials. Vyndaqel will be made available to those who can’t afford the drug through patient assistance foundations. The makers are also in talks with the insurers for the drug to be reimbursable.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Pfizer gets U.S. approval for $225,000 a year heart drug
The U.S. Food and Drug Administration on Monday approved Pfizer Inc’s oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said. Pfizer, which has touted tafamidis as a potential blockbuster product, set a list price of..